目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫...目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫PBS作为对照,每组10只。初次免疫后第7、14、21、28、35和42天采集血清,间接ELISA法检测血清中针对Delta株病毒S和N蛋白的结合抗体效价,微量中和试验检测针对Delta株病毒的中和抗体效价。初次免疫后第42天,取小鼠脾脏,进行Elispot检测,评价细胞免疫水平。结果初次免疫后第7天即可检测到S蛋白结合抗体,加强免疫后抗体效价进一步升高,至第21天抗体几何平均滴度(geometric mean titer,GMT)为89144;而初次免疫后N蛋白结合抗体水平较低,加强免疫后迅速升高,与S蛋白抗体水平相当。初次免疫后第7、14天小鼠中和抗体阳转数为4/10和8/10,加强免疫后全部小鼠抗体阳转,中和抗体GMT达391。初次免疫后第42天,疫苗组IFNγ和IL-2平均斑点数均显著高于对照组(t分别为8.094和13.08,P均<0.0001)。结论SARS-CoV-2灭活疫苗2次免疫能够有效刺激小鼠产生针对Delta株病毒的体液免疫和细胞免疫。展开更多
目的分析自噬与新型冠状病毒感染(COVID-19)研究中的主要研究主题和热点,揭示该领域的研究趋势和未来方向。方法采用Web of Science核心数据库,检索自2020年1月1日至2024年4月18日发表的与自噬和COVID-19相关的英文文献。利用文献计量...目的分析自噬与新型冠状病毒感染(COVID-19)研究中的主要研究主题和热点,揭示该领域的研究趋势和未来方向。方法采用Web of Science核心数据库,检索自2020年1月1日至2024年4月18日发表的与自噬和COVID-19相关的英文文献。利用文献计量学方法和CiteSpace软件工具进行文献可视化分析。结果自2020年以来,自噬与COVID-19相关的文献数量呈爆发性增长,总共纳入514篇文献。发表论文最多的机构为中国科学院,研究影响最大的科研机构为加州大学系统。研究热点包括自噬在SARS-CoV-2感染中的作用、自噬相关的信号通路、自噬与炎症反应的关系以及自噬作为潜在治疗靶点的研究。通过关键词分析生成的知识图谱显示了自噬、SARS-CoV-2、炎症、抗病毒反应等关键词之间的关联。关键词的聚类分析揭示了自噬在病毒复制、抗炎和免疫调节以及细胞死亡中的作用是当前研究的主要方向。结论自噬在COVID-19的发病机制和治疗中扮演着重要角色。可视化分析为理解自噬与COVID-19复杂的相互作用提供了新的视角,并指出自噬在长新冠和新冠后综合征中的作用是未来研究的主要方向。展开更多
The emergence of the SARS-CoV-2 virus resulted in a health and economic crisis worldwide. Although everyone is susceptible to COVID-19, the elderly have compromised immune systems and often suffer from chronic underly...The emergence of the SARS-CoV-2 virus resulted in a health and economic crisis worldwide. Although everyone is susceptible to COVID-19, the elderly have compromised immune systems and often suffer from chronic underlying diseases, which makes them more vulnerable. This study aims to assess variation in COVID-19 vaccine distribution patterns across different age groups in European countries and to understand the extent to which European countries have prioritized vulnerable age groups (age > 70) in their vaccination programs. The study utilized open data from the European Center for Disease Prevention and Control (ECDC) and employed an observational, retrospective study design to examine the distribution of the COVID-19 vaccine among various age groups in several European countries from September 2021 to September 2023. Results reveal that vaccination rates increase with age, peaking at the 25 - 49 age group (1.34 × 10−4), after which there was a decline in vaccination rate. Analysis of variance (ANOVA) was used to investigate the equality of vaccination rates across the 29 countries in Europe, which resulted in a p-value of 70) during the study period as no country achieved the 70% coverage aimed by WHO. Continuous efforts must be made to ensure larger coverage of COVID-19 vaccination among this vulnerable population in order to protect them from severe outcomes in this region.展开更多
文摘目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫PBS作为对照,每组10只。初次免疫后第7、14、21、28、35和42天采集血清,间接ELISA法检测血清中针对Delta株病毒S和N蛋白的结合抗体效价,微量中和试验检测针对Delta株病毒的中和抗体效价。初次免疫后第42天,取小鼠脾脏,进行Elispot检测,评价细胞免疫水平。结果初次免疫后第7天即可检测到S蛋白结合抗体,加强免疫后抗体效价进一步升高,至第21天抗体几何平均滴度(geometric mean titer,GMT)为89144;而初次免疫后N蛋白结合抗体水平较低,加强免疫后迅速升高,与S蛋白抗体水平相当。初次免疫后第7、14天小鼠中和抗体阳转数为4/10和8/10,加强免疫后全部小鼠抗体阳转,中和抗体GMT达391。初次免疫后第42天,疫苗组IFNγ和IL-2平均斑点数均显著高于对照组(t分别为8.094和13.08,P均<0.0001)。结论SARS-CoV-2灭活疫苗2次免疫能够有效刺激小鼠产生针对Delta株病毒的体液免疫和细胞免疫。
文摘目的分析自噬与新型冠状病毒感染(COVID-19)研究中的主要研究主题和热点,揭示该领域的研究趋势和未来方向。方法采用Web of Science核心数据库,检索自2020年1月1日至2024年4月18日发表的与自噬和COVID-19相关的英文文献。利用文献计量学方法和CiteSpace软件工具进行文献可视化分析。结果自2020年以来,自噬与COVID-19相关的文献数量呈爆发性增长,总共纳入514篇文献。发表论文最多的机构为中国科学院,研究影响最大的科研机构为加州大学系统。研究热点包括自噬在SARS-CoV-2感染中的作用、自噬相关的信号通路、自噬与炎症反应的关系以及自噬作为潜在治疗靶点的研究。通过关键词分析生成的知识图谱显示了自噬、SARS-CoV-2、炎症、抗病毒反应等关键词之间的关联。关键词的聚类分析揭示了自噬在病毒复制、抗炎和免疫调节以及细胞死亡中的作用是当前研究的主要方向。结论自噬在COVID-19的发病机制和治疗中扮演着重要角色。可视化分析为理解自噬与COVID-19复杂的相互作用提供了新的视角,并指出自噬在长新冠和新冠后综合征中的作用是未来研究的主要方向。
文摘The emergence of the SARS-CoV-2 virus resulted in a health and economic crisis worldwide. Although everyone is susceptible to COVID-19, the elderly have compromised immune systems and often suffer from chronic underlying diseases, which makes them more vulnerable. This study aims to assess variation in COVID-19 vaccine distribution patterns across different age groups in European countries and to understand the extent to which European countries have prioritized vulnerable age groups (age > 70) in their vaccination programs. The study utilized open data from the European Center for Disease Prevention and Control (ECDC) and employed an observational, retrospective study design to examine the distribution of the COVID-19 vaccine among various age groups in several European countries from September 2021 to September 2023. Results reveal that vaccination rates increase with age, peaking at the 25 - 49 age group (1.34 × 10−4), after which there was a decline in vaccination rate. Analysis of variance (ANOVA) was used to investigate the equality of vaccination rates across the 29 countries in Europe, which resulted in a p-value of 70) during the study period as no country achieved the 70% coverage aimed by WHO. Continuous efforts must be made to ensure larger coverage of COVID-19 vaccination among this vulnerable population in order to protect them from severe outcomes in this region.
